XML 52 R36.htm IDEA: XBRL DOCUMENT
v3.24.1

Note 14 - Parent Company Financial Statements (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Notes Tables |
Condensed Balance Sheet [Table Text Block] |
|  | 2023 |  |  | 2022 |
Assets |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 1,454 |  |  | $ | 286 |
Receivables due from subsidiaries |  |  | 110,083 |  |  |  | 98,780 |
Prepaid expenses |  |  | 437 |  |  |  | 611 |
Other current assets |  |  | 12 |  |  |  | 7 |
Total current assets |  |  | 111,986 |  |  |  | 99,684 |
Investment in Aemetis Property Keyes, Inc. |  |  | 1,556 |  |  |  | 1,274 |
Investment in Aemetis International, Inc. |  |  | 12,059 |  |  |  | 6,659 |
Investment in Aemetis Advanced Products Riverbank, Inc. |  |  | 638 |  |  |  | 173 |
Investment in AE Advanced Products Keyes , Inc. |  |  | 246 |  |  |  | - |
Total investments in Subsidiaries, net of advances |  |  | 14,499 |  |  |  | 8,106 |
Property, plant and equipment, net |  |  | 149 |  |  |  | 135 |
Other assets |  |  | 2,096 |  |  |  | 2,377 |
Total Assets |  | $ | 128,730 |  |  | $ | 110,302 |
Liabilities & stockholders' deficit |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |
Accounts payable |  | $ | 3,633 |  |  | $ | 2,934 |
Mandatorily redeemable Series B convertible preferred |  |  | 4,521 |  |  |  | 4,082 |
Other current liabilities |  |  | 5,031 |  |  |  | 4,269 |
Total current liabilities |  |  | 13,185 |  |  |  | 11,285 |
Long term liabilities: |  |  |  |  |  |  |  |
Operating lease liability |  |  | 1,716 |  |  |  | 2,047 |
Subsidiary obligation in excess of investment |  |  |  |  |  |  |  |
Investment in AE Advanced Fuels, Inc. |  |  | 220,571 |  |  |  | 177,856 |
Investment in Aemetis Americas, Inc |  |  | 202 |  |  |  | 205 |
Investment in Aemetis Biofuels, Inc. |  |  | 2,721 |  |  |  | 2,738 |
Investment in Aemetis Technologies, Inc. |  |  | 4,868 |  |  |  | 4,716 |
Investment in AE Advanced Products Keyes , Inc. |  |  | - |  |  |  | 270 |
Investment in Aemetis Health Products, Inc. |  |  | 2,084 |  |  |  | 2,076 |
Investment in Goodland Advanced Fuels, Inc. |  |  | 22,982 |  |  |  | 16,869 |
Investment in Aemetis Biogas LLC |  |  | 70,471 |  |  |  | 91,292 |
Investment in Aemetis Carbon Capture Inc |  |  | 5,895 |  |  |  | 2,323 |
Investment in Aemetis Properties Riverbank, Inc. |  |  | 1,012 |  |  |  | 479 |
Total subsidiary obligation in excess of investment |  |  | 330,806 |  |  |  | 298,824 |
Total long term liabilities |  |  | 332,522 |  |  |  | 300,871 |
Stockholders' deficit |  |  |  |  |  |  |  |
Series B Preferred convertible stock |  |  | - |  |  |  | 1 |
Common stock |  |  | 41 |  |  |  | 36 |
Additional paid-in capital |  |  | 264,058 |  |  |  | 232,546 |
Accumulated deficit |  |  | (475,405 | ) |  |  | (428,985 | )
Accumulated other comprehensive loss |  |  | (5,671 | ) |  |  | (5,452 | )
Total stockholders' deficit |  |  | (216,977 | ) |  |  | (201,854 | )
Total liabilities & stockholders' deficit |  | $ | 128,730 |  |  | $ | 110,302 |
Condensed Income Statement [Table Text Block] |
|  | 2023 |  |  | 2022 |
Equity in subsidiary losses |  | $ | (25,370 | ) |  | $ | (91,561 | )
Selling, general and administrative expenses |  |  | 19,218 |  |  |  | 15,203 |
Operating loss |  |  | (44,588 | ) |  |  | (106,764 | )
Other (income) expense |  |  |  |  |  |  |  |
Interest expense |  |  | 1,073 |  |  |  | 806 |
Debt related fees and amortization expense |  |  | 781 |  |  |  | 1,581 |
Other income |  |  | (30 | ) |  |  | (1,400 | )
Loss before income taxes |  |  | (46,412 | ) |  |  | (107,751 | )
Income tax expense |  |  | 8 |  |  |  | 7 |
Net loss |  |  | (46,420 | ) |  |  | (107,758 | )
Other comprehensive loss |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  |  | (219 | ) |  |  | (1,102 | )
Comprehensive loss |  | $ | (46,639 | ) |  | $ | (108,860 | )
Condensed Cash Flow Statement [Table Text Block] |
|  | 2023 |  |  | 2022 |
Operating activities: |  |  |  |  |  |  |  |
Net loss |  |  | (46,420 | ) |  |  | (107,758 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Stock-based compensation |  |  | 7,660 |  |  |  | 6,410 |
Depreciation |  |  | 51 |  |  |  | 29 |
Debt related fees and amortization expense |  |  | 782 |  |  |  | 1,776 |
Subsidiary portion of net losses |  |  | 25,370 |  |  |  | 91,561 |
Gain on litigation |  |  | - |  |  |  | (1,400 | )
Warrants issued for working capital agreement |  |  | 409 |  |  |  | - |
Changes in assets and liabilities: |  |  |  |  |  |  |  |
Prepaid expenses |  |  | (608 | ) |  |  | 111 |
Accounts payable |  |  | 699 |  |  |  | (90 | )
Accrued interest expense |  |  | 785 |  |  |  | 778 |
Other liabilities |  |  | 85 |  |  |  | (4,625 | )
Other assets |  |  | 276 |  |  |  | 207 |
Net cash used in operating activities |  |  | (10,911 | ) |  |  | (13,001 | )
Investing activities: |  |  |  |  |  |  |  |
Capital expenditures |  |  | (65 | ) |  |  | (128 | )
Subsidiary advances, net |  |  | (9,707 | ) |  |  | 1,222 |
Net cash provided by (used in) investing activities |  |  | (9,772 | ) |  |  | 1,094 |
Financing activities: |  |  |  |  |  |  |  |
Proceeds from the exercise of stock options |  |  | 133 |  |  |  | 206 |
Proceeds from issuance of common stock in equity offering |  |  | 21,718 |  |  |  | 11,987 |
Net cash provided by financing activities |  |  | 21,851 |  |  |  | 12,193 |
Net increase in cash, cash equivalents, and restricted cash |  |  | 1,168 |  |  |  | 286 |
Cash, cash equivalents and restricted cash at beginning of period |  |  | 286 |  |  |  | - |
Cash, cash equivalents, and restricted cash at end of period |  | $ | 1,454 |  |  | $ | 286 |
Supplemental disclosures of cash flow information, cash paid: |  |  |  |  |  |  |  |
Income taxes paid |  |  | 7 |  |  |  | 7 |
Supplemental disclosures of cash flow information, non-cash transactions: |  |  |  |  |  |  |  |
Fair value of warrants issued to subordinated debt holders |  |  | 1,278 |  |  |  | 1,939 |
Fair value of stock issued to a related party for guarantee fees |  |  | - |  |  |  | 2,012 |
Fair value of warrants issued for capital expenditures |  |  | 318 |  |  |  | - |
Fair value of warrants issued to lender for debt issuance costs |  |  | - |  |  |  | 3,158 |
Fair value of stock issued to lender |  |  | - |  |  |  | 1,335 |

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph (a) -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph (a) -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph (a) -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration